利妥昔单抗二线治疗成人免疫性血小板减少症的长期结局:RITP研究随访
RITP是一项双盲随机、随访78周的试验,109例对糖皮质激素应答不足的成人ITP患者随机接受利妥昔单抗或安慰剂。
核心结论
- 多数利妥昔单抗治疗患者最终复发,但应答持续时间更长且脾切除率有降低趋势。
研究设计与样本
- RITP为双盲随机对照试验,随访78周,纳入109例对糖皮质激素应答不足的成人ITP患者。
- 扩展随访回顾性收集初始研究中未脾切除的84例患者中的72例(83%),随机化后中位随访72个月(IQR 62-82)。
临床怎么用
- 对于糖皮质激素应答不足的成人ITP,利妥昔单抗二线治疗可获得更长的应答持续时间。
- 利妥昔单抗治疗虽多数患者最终复发,但可推迟或减少脾切除,需权衡个体化治疗。
局限性
- 扩展随访为回顾性数据收集,仅覆盖初始未脾切除患者中的72例(83%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RITP was a double-blind randomized, 78-week follow-up trial in which 109 adults with immune thrombocytopenias (ITP) who failed to achieve adequate response to steroids, were randomized to receive rituximab or placebo. Here, we provide the duration of response, splenectomy and mortality rates based on extended follow-up after completion of the RITP study. Extended follow-up data were retrospectively collected for 72 (83%) patients out of the 84 patients who were not splenectomized during the initial RITP study. For the present analysis, median [interquartile range] duration of follow-up after randomization was 72 [62-82] months. Median duration of response among patients who achieved an initial response was significantly longer in patients who received rituximab (8·2 [5·5-16·7] months) as compared to placebo (1·8 [1·3-3·6] months), P = 0·036. Overall, 35 patients underwent splenectomy (13 in the rituximab, and 22 in the placebo arm, P = 0·12). Eleven patients (10%) died during the study: five in the rituximab and six in the placebo arms, including four deaths from severe bleeding. Although most rituximab-treated patients eventually relapsed, a longer duration of response and a trend towards lower splenectomy rate were observed in rituximab-treated patients.
引用
- Tjønnfjord E, Holme PA, Darne B, et al. Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia - Follow-up of the RITP study. Br J Haematol. 2020. PMID: 32342497. doi:10.1111/bjh.16672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。